Navigation Links
Amarantus BioSciences Issues CEO Letter to Shareholders
Date:11/19/2012

from thought-leaders and have offset some of the financial burden of running proof-of-concept studies. The Company has already taken steps to improve our prospects in future partnering discussions from a corporate structure standpoint, and we will continue to improve MANF's prospects by focusing on further differentiating MANF from its competition, especially in Parkinson's disease. To further this objective, we have added certain key advisors to assist management in preparing a winning strategy to obtain the most value from our MANF program. With these new additions, we have gained access to significant intellectual capital, as well as invaluable insight into the realm of preparing both our asset and our corporation for successful partnerships.

MANF's current lead indication is Parkinson's disease, an area where we have produced very promising results. We have also achieved positive data in Traumatic Brain Injury (TBI) through our collaboration with Banyan Biomarkers. Our #C4CT program has attracted significant attention among NFL players and other professional athletes who have suffered from brain injuries, and we intend to leverage those relationships to raise awareness of MANF's potential role in TBI. In addition to Parkinson's disease and TBI, MANF has shown to be effective across a broad range of indications. The recent publication of myocardial infarction data validating a MANF-based approach has added significant value to our patent portfolio. Myocardial Infarction is a $5B market where there are currently no approved drugs to address the ischemia and reperfusion related injuries associated with heart attacks.

Perhaps most interesting from a time-to-market standpoint, is the emerging evidence that MANF has activity in certain rare and ultra-rare orphan diseases. The orphan drug strategy that management is pursuing will seek a path to commercialize MANF as expeditiously and cost-effectively as possible, and potentially
'/>"/>

SOURCE Amarantus BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amarantus BioSciences Secures $1.1 Million in Financing
2. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
3. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
4. Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
5. TheStockRadio.com Interviews Amarantus BioSciences President & CEO Gerald E. Commissiong
6. Amarantus BioSciences Featured in BioWorld Today, Brewer Sports Symposium and Opportunist Magazine
7. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
8. IntelliCell BioSciences Announces It Will Present and Run Workshop at the 10th Annual Commercialization of Regenerative Medicine in London
9. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
10. Neurocrine Biosciences Reports Third Quarter 2012 Results
11. IntelliCell BioSciences Announces Myron Z. Holubiak Joins the IntelliCell BioSciences Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... German . ... have demonstrated a new kind of building block for ... chips could be based on three-dimensional arrangements of nanometer-scale ... of the semiconductor industry CMOS fabrication of silicon ... collaborators at the University of Notre Dame are exploring ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... to kill nematodes. Nematodes are microscopic parasitic roundworms, ... water, and inside other plants and animals. Nematicides ... volatility or other properties promoting migration through the ... more than 1,000 plant-parasitic nematodes. With more than ...
(Date:9/30/2014)... -- CORD:USE Cord Blood Bank – www.corduse.com ... into an Equity and Exclusive Services Agreement with Tianhe Stem ... patented technologies for the isolation of human cord blood-derived ... performing Phase I/II clinical trials in China ... Tianhe,s Stem Cell Educator Therapy showing that the therapy ...
(Date:9/30/2014)... Md., Sept. 30, 2014 BioHealth Innovation, ... commercializing market-relevant biohealth innovations and increasing access to early-stage ... today that venture capitalist, Tania Fernandez , Ph.D., ... Dr. Fernandez will be a member of the management ... provide up to $50 million in seed and early-stage ...
Breaking Biology Technology:A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2
... Willebrords 1 and Bart Moyson 2 , ... Development, a division of Janssen Pharmaceutica N.V., Laboratory of Virology, Beerse, Belgium ... Life Sciences Benelux NV, Teralfene, Belgium , ... of this paper is to report the performance obtained by dispensing 1μL organic ...
... Jeff Cunningham and Lynn Jordan ... Inc., Applications Laboratory, Hopkinton, Massachusetts, USA , ... The ability to continuously dispense reagents across multi-well plates ... high throughput laboratories. Equally important, however, is the precision that can ...
... , Bruce R. Conklin 1 , Laurence L. Brunton ... Anne T. Ferguson 4 , 1 Gladstone ... Pharmacology 2 and Medicine 3 , ... 4 Molecular Devices Corp., 1311 Orleans Drive, Sunnyvale, CA 94089, , , ...
Cached Biology Technology:96 Well Pipetting Precision Testing Using the Sciclone ALH with a 384 Fixed-Cannula Array 296 Well Pipetting Precision Testing Using the Sciclone ALH with a 384 Fixed-Cannula Array 3Sciclone ALH Bulk Dispense Precision Testing 2Gq-coupled Receptor Assays Using FLEXstation 2Gq-coupled Receptor Assays Using FLEXstation 3Gq-coupled Receptor Assays Using FLEXstation 4Gq-coupled Receptor Assays Using FLEXstation 5Gq-coupled Receptor Assays Using FLEXstation 6Gq-coupled Receptor Assays Using FLEXstation 7
(Date:9/30/2014)... Journal of Medicine reports positive results of a ... the subset of lung cancer marked by rearrangement of ... patients with advanced non-small cell lung cancer testing positive ... percent, with 3 complete responses and 33 partial responses. ... the disease to resume its growth after being slowed ...
(Date:9/30/2014)... research, involving mice and published in the October 2014 ... , suggests that just because you can do ... team of Italian scientists have found that using marijuana ... immune system. This damage may result in autoimmune diseases ... bowel disease and rheumatoid arthritis in adulthood. , "I ...
(Date:9/30/2014)... is available in German . ... behavioural response to risky situations such as exposure to ... now found in a long-term study on different populations ... metabolic rate and ambient temperature. High metabolic rates and ... in these scenarios birds were more likely to approach ...
Breaking Biology News(10 mins):NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2Adolescent exposure to thc may cause immune systems to go up in smoke 2Risky metabolism 2
... Can the hold that Intelligent Design theorists have in ... a leading American evolutionist, makes the case for Darwin ... Reporting from the front lines of America's struggle over ... (University College London) on 16th November. , In his ...
... inoculate everyone in the United States could be grown ... plants, a University of Central Florida molecular biologist has ... UCF professor Henry Daniell's laboratory through the genetic engineering ... later by National Institutes of Health researchers. The results ...
... special green-algae gene into neurons of the tiny, ... to elicit specific behavioral responses by simply illuminating ... way for better understanding of how neurons communicate ... behavior in intact, living organisms. Generally speaking, detailed ...
Cached Biology News:'Creationism is not science' ?making the case for Darwin at UCL 2Effective, safe anthrax vaccine can be grown in tobacco plants 2Effective, safe anthrax vaccine can be grown in tobacco plants 3Algal protein in worm neurons allows remote control of behavior by light 2
Fingerprinting II database sharing tools is an optional module for the Fingerprinting II Basic software package that enables peer-to-peer data exchange over the internet and provides external databas...
... Fingerprinting II Informatix ... an optional module ... component analysis, multidimensional ... and MANOVA, and ...
Fingerprinting II comparative quantification and polymorphism analysis is an optional module that adds comparative quantification and polymorphism analysis functions to the Fingerprinting II Basic so...
... instrument is the most advanced thermal cycler ... thermal performance, the Dyad also boasts graphical ... point-and-click navigation via touch pad or mouse. ... and economically expanded to a four-bay system ...
Biology Products: